Angiographic Outcomes in the PLATO

V. Kunadian, S.K. James, D.M. Wojdyla, C. Zorkun, J. Wu, R.F. Storey,Ph.G. Steg, H. Katus, H. Emanuelsson, J. Horrow, J. Maya,L. Wallentin, R.A. Harrington, C.M. Gibson


1. Alexopoulos D., Xanthopoulou I., Gkizas V. et al. Randomized assessment of ticagrelor versus prasugrel antiplatelet effects in patients with ST-segment-elevation myocardial infarction // Circ. Cardiovasc. Interv.– 2012.– Vol. 5.– P. 797–804. 
2. Anderson S.D., Shah N.K., Yim J., Epstein B.J. Efficacy and safety of ticagrelor: A reversible P2Y12 receptor antagonist // Ann. Pharmacother.– 2010.– Vol. 44.– P. 524–537.
3. Berger J.S., Roe M.T., Gibson C.M. et al. Safety and feasibility of adjunctive antiplatelet therapy with intravenous elinogrel, a direct-acting and reversible P2Y12 ADP-receptorantagonist, before primary percutaneous intervention in patients with ST-elevation myocardial infarction: the Early Rapid Reversal of Platelet Thrombosis With Intravenous Elinogrel Before PCI To Optimize Reperfusion in Acute Myocardial Infarction (ERASE MI) pilot trial // Am. Heart J.– 2009.– Vol. 158.– P. 998–1004.
4. Gabriel H.M., Oliveira J.A., da Silva P. C. et al. Early administration of abciximab bolus in the emergency department improves angiographic outcome after primary PCI as assessed by TIMI frame count: results of the early Reopro Administration in Myocardial Infarction (ERAMI) trial // Catheter Cardiovasc. Interv.– 2006.– Vol. 68.– P. 218–224. 
5. Gibson C.M., Cannon C.P., Daley W.L. et al. TIMI frame count: a quantitative method of assessing coronary artery flow // Circulation.– 1996.– Vol. 93.– P. 879–888.
6. Gibson C.M., Cannon C.P., Murphy S.A. et al. Relationship of IMI myocardial perfusion grade to mortality after administration of thrombolytic drugs // Circulation.– 2000.– Vol. 101.– P. 125–130.
7. Gibson C.M., Cannon C.P., Murphy S.A. et al., for the TIMIStudy Group. Relationship of the TIMI myocardial perfusion grades, flow grades, frame count, and percutaneous coronary intervention to long-term outcomes after thrombolytic administration in acute myocardial infarction // Circulation.– 2002.– Vol. 105.– P. 1909–1913.
8. Gibson C.M., Cohen D.J., Cohen E.A. et al. Effect of eptifibatide on coronary flow reserve following coronary stent implantation (an ESPRIT substudy): Enhanced Suppression of the Platelet IIb/IIIa Receptor With Integrilin Therapy // Am. J. Cardiol.– 2001.– Vol. 87.– P. 1293–1295.
9. Gibson C.M., Morrow D.A., Murphy S.A. et al., for the TIMI Study Group. A randomized trial to evaluate the relative protection against post-percutaneous coronary intervention microvascular dysfunction, ischemia, and inflammation among antiplatelet and antithrombotic agents: the PROTECT-TIMI-30 trial // J. Am. Coll. Cardiol.– 2006.– Vol. 47.– P. 2364–2373.
10. Gibson C.M., de Lemos J.A., Murphy S.A. et al. Combination therapy with abciximab reduces angiographically evident thrombus in acute myocardial infarction: a TIMI 14 substudy // Circulation.– 2001.– Vol. 103.– P. 2550–2554.
11. Gibson C.M., Murphy S.A., Morrow D.A. et al. Angiographic perfusion score: an angiographic variable that integrates both epicardial and tissue level perfusion before and after facilitated percutaneous coronary intervention in acute myocardial infarction // Am. Heart J.– 2004.– Vol. 148.– P. 336–340.
12. Gurbel P.A., Bliden K.P., Butler K. et al. Randomized doubleblindassessment of the ONSET and OFFSET of the antiplatelet effects of ticagrelor versus clopidogrel in patients with stable coronary artery disease: the ONSET/OFFSET study // Circulation.– 2009.– Vol. 120.– P. 2577–2585.
13. Gurbel P.A., Bliden K.P., Butler K. et al. Response to ticagrelor in clopidogrel nonresponders and responders and effect of switching therapies: the RESPOND study // Circulation.– 2010.– Vol. 121.– P. 1188–1899.
14. Husted S., Emanuelsson H., Heptinstall S. et al. Pharmacodynamics, pharmacokinetics, and safety of the oral reversible P2Y12 antagonist AZD6140 with aspirin in patients with atherosclerosis: a double-blind comparison to clopidogrel with aspirin // Eur. Heart J.– 2006.– Vol. 27.– P. 1038–1047.
15. Husted S.E., Storey R.F., Bliden K. et al. Pharmacokinetics and pharmacodynamics of ticagrelor in patients with stable coronary artery disease: results from the ONSET-OFFSET and RESPOND studies // Clin. Pharmacokinet.– 2012.– Vol. 51.– P. 397–409.
16. James S., Akerblom A., Cannon C.P. et al. Comparison of ticagrelor, the first reversible oral P2Y12 receptor antagonist, with clopidogrel in patients with acute coronary syndromes: rationale, design, and baseline characteristics of the Platelet Inhibition and Patient Outcomes (PLATO) trial // Am. Heart J.– 2009.– Vol. 157.– P. 599–605.
17. Kunadian V., Zorkun C., Williams S.P. et al. Intracoronary pharmacotherapy in the management of coronary microvascular dysfunction // J. Thromb. Thrombolysis.– 2008.– Vol. 26.– P. 234–242.
18. Petronio A.S., Rovai D., Musumeci G. et al. Effects of abciximab on microvascular integrity and left ventricular functional recovery in patients with acute infarction treated by primary coronary angioplasty // Eur. Heart J.– 2003.– Vol. 24.– P. 67–76.
19. Schneider D.J. Anti-platelet therapy: glycoprotein IIb-IIIa antagonists // Br. J. Clin. Pharmacol.– 2011.– Vol. 72.– P. 672– 682.
20. Schneider D.J. Mechanisms potentially contributing to the reduction in mortality associated with ticagrelor therapy // J. Am. Coll. Cardiol.– 2011.– Vol. 57.– P. 685–687.
21. Stoel M.G., Marques K.M., de Cock C.C. et al. High dose adenosine for suboptimal myocardial reperfusion after primary PCI: a randomized placebo-controlled pilot study // Catheter. Cardiovasc. Interv.– 2008.– Vol. 71.– P. 283–289.
22. Storey R.F., Husted S., Harrington R.A. et al. Inhibition of platelet aggregation by AZD6140, a reversible oral P2Y12 receptor antagonist, compared with clopidogrel in patients with acute coronary syndromes // J. Am. Coll. Cardiol.– 2007.– Vol. 50.– P. 1852–1856.
23. Teng R., Butler K. Pharmacokinetics, pharmacodynamics, tolerability and safety of single ascending doses of ticagrelor, a reversibly binding oral P2Y12 receptor antagonist, in healthy subjects // Eur. J. Clin. Pharmacol. 2010.– Vol. 66.– P. 487–496.
24. TIMI Study Group. The Thrombolysis In Myocardial Infarction (TIMI) trial: phase I findings // New Engl. J. Med.– 1985.– Vol. 312.– P. 932–936.
25. Van Giezen J.J., Sidaway J., Glaves P. et al. Ticagrelor inhibits adenosine uptake in vitro and enhances adenosine-mediated hyperemia responses in a canine model // J. Cardiovasc. Pharmacol. Ther.– 2012.– Vol. 17.– P. 164–172.

26. Vijayalakshmi K., Kunadian B., Whittaker V.J. et al. Impact of catheter sizes and intracoronary glyceryl trinitrate on the TIMI frame count when digital angiograms are acquired at lower frame rates during elective angiography and PCI // Acute Card. Care.– 2007.– Vol. 9.– P. 231–238. 27. Vijayalakshmi K., Whittaker V.J., Kunadian B. et al. Prospective, randomised, controlled trial to study the effect of intracoronary injection of verapamil and adenosine on coronary blood flow during percutaneous coronary intervention in patients with acute coronary syndromes // Heart.– 2006.– Vol. 92.– P. 1278–1284. 28. Wallentin L., Becker R.C., Budaj A. et al., for the PLATO Investigators. Ticagrelor versus clopidogrel in patients with acute coronary syndromes // New Engl. J. Med.– 2009.– Vol. 361.– P. 1045–1057. 29. Wittfeldt A., Emanuelsson H., Brandrup-Wognsen G. et al. Ticagrelor enhances adenosine-induced coronary vasodilatory responses in humans // J. Am. Coll. Cardiol.– 2013.– Vol. 61.– P. 723–727.

[PDF] [Contents]